Murepavadin
A macrocyclic peptidomimetic antibiotic targeting Pseudomonas aeruginosa.
- Evidence grade
- CEarly Human Research
Early Human Research
- Regulatory status
- Investigational
Investigational; not FDA-approved for the uses discussed.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A macrocyclic peptidomimetic antibiotic targeting Pseudomonas aeruginosa.
Investigational; not FDA-approved for the uses discussed.
The exact active 2026 inhaled phase was not verified, and IV findings do not automatically apply to inhalation.
Why It's Being Studied
- Pseudomonas infections
- LptD targeting
Mechanism of Action
It binds outer-membrane protein LptD, disrupting bacterial membrane biogenesis.
It binds outer-membrane protein LptD, disrupting bacterial membrane biogenesis. The exact active 2026 inhaled phase was not verified, and IV findings do not automatically apply to inhalation.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Pseudomonas infections
- LptD targeting
- Intravenous clinical research
- Inhaled clinical research
Evidence Summary
Intravenous development reached phase 3 but stopped after renal-safety concerns; inhaled development subsequently entered human trials.
Higher tiers carry more weight. Filled tiers have evidence for Murepavadin; tap to read it.
- Intravenous development reached phase 3 but stopped after renal-safety concerns; inhaled development subsequently entered human trials.
1 cited sources.
- Regulatory document1
Human clinical evidence
- Intravenous development reached phase 3 but stopped after renal-safety concerns; inhaled development subsequently entered human trials.
Reported Adverse Events in Research
- Renal safety concerns from IV development are significant; inhaled exposure requires its own safety assessment.
Limitations of Current Evidence
- The exact active 2026 inhaled phase was not verified, and IV findings do not automatically apply to inhalation.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Murepavadin | Trofinetide | |
|---|---|---|
| Evidence grade | C — Early Human Research | B — Moderate Human Evidence |
| Regulatory status | Investigational | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Intravenous clinical research, Inhaled clinical research | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Regulatory document
Murepavadin — regulatory document